These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37313374)

  • 1. Guidance on interim analysis methods in clinical trials.
    Ciolino JD; Kaizer AM; Bonner LB
    J Clin Transl Sci; 2023; 7(1):e124. PubMed ID: 37313374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A flexible futility monitoring method with time-varying conditional power boundary.
    Ying Zhang ; Clarke WR
    Clin Trials; 2010 Jun; 7(3):209-18. PubMed ID: 20423927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring factors associated with views on sharing of certain interim trial result measures by the data safety monitoring board (DSMB) with non-DSMB members.
    Borg Debono V; Mbuagbaw L; Paul J; Buckley N; Thabane L
    Trials; 2018 Nov; 19(1):621. PubMed ID: 30419939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sharing interim trial results by the Data Safety Monitoring Board with those responsible for the trial's conduct and progress: a narrative review.
    Borg Debono V; Mbuagbaw L; Thabane L
    Trials; 2017 Mar; 18(1):120. PubMed ID: 28279205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survey of professional views on sharing interim results by the Data Safety Monitoring Board (DSMB): what to share, with whom and why.
    Borg Debono V; Mbuagbaw L; Paul J; Buckley N; Thabane L
    Trials; 2018 May; 19(1):281. PubMed ID: 29784030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Data and safety monitoring during randomized controlled trials of nursing interventions.
    Artinian NT; Froelicher ES; Vander Wal JS
    Nurs Res; 2004; 53(6):414-8. PubMed ID: 15586138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the Data and Safety Monitoring Board in a clinical trial: the CRISIS study.
    Holubkov R; Casper TC; Dean JM; Anand KJ; Zimmerman J; Meert KL; Newth CJ; Berger J; Harrison R; Willson DF; Nicholson C;
    Pediatr Crit Care Med; 2013 May; 14(4):374-83. PubMed ID: 23392377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility.
    Walter SD; Han H; Briel M; Guyatt GH
    Stat Med; 2017 Apr; 36(9):1506-1518. PubMed ID: 28183155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic survey of randomised trials that stopped early for reasons of futility.
    Walter SD; Han H; Guyatt GH; Bassler D; Bhatnagar N; Gloy V; Schandelmaier S; Briel M
    BMC Med Res Methodol; 2020 Jan; 20(1):10. PubMed ID: 31948397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Data and safety monitoring policy for National Institute of Allergy and Infectious Diseases clinical trials.
    Dixon DO; Weiss S; Cahill K; Fox L; Love J; McNamara J; Soto-Torres LE
    Clin Trials; 2011 Dec; 8(6):727-35. PubMed ID: 22024105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of Predictive Analyses for Interim Decisions in Clinical Trials.
    Avalos-Pacheco A; Ventz S; Arfè A; Alexander BM; Rahman R; Wen PY; Trippa L
    JCO Precis Oncol; 2023 Feb; 7():e2200606. PubMed ID: 36848613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting clinical trial results based on announcements of interim analyses.
    Broglio KR; Stivers DN; Berry DA
    Trials; 2014 Mar; 15():73. PubMed ID: 24607270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sharing some interim data in trial monitoring can mislead or unmask trial investigators: A scenario-based survey of trial experts.
    Borg Debono V; Mbuagbaw L; Paul J; Buckley N; Thabane L
    Contemp Clin Trials Commun; 2017 Sep; 7():81-85. PubMed ID: 29696172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interim data monitoring in cluster randomised trials: Practical issues and a case study.
    Hemming K; Martin J; Gallos I; Coomarasamy A; Middleton L
    Clin Trials; 2021 Oct; 18(5):552-561. PubMed ID: 34154426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interim monitoring in a treatment strategy trial with a composite primary endpoint.
    Kang M; Grund B; Hunsberger S; Glidden D; Volberding P
    Contemp Clin Trials; 2019 Nov; 86():105846. PubMed ID: 31520741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the data safety and monitoring board in an international trial.
    NIMH Collaborative HIV/STD Prevention Trial
    AIDS; 2007 Apr; 21 Suppl 2():S99-102. PubMed ID: 17413269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias.
    Tharmanathan P; Calvert M; Hampton J; Freemantle N
    BMC Med Res Methodol; 2008 Mar; 8():12. PubMed ID: 18366697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
    Ryan EG; Brock K; Gates S; Slade D
    BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.